Erythropoietin Enzyme Immunoassay

FDA 510(k) K882686 · Amgen, Inc.

Substantially Equivalent

510(k) numberK882686

Submission

Device name
Erythropoietin Enzyme Immunoassay
Applicant
Amgen, Inc.
Thousand Oaks, CA, US
Received
June 30, 1988
Decision date
December 20, 1988
Decision
Substantially Equivalent (SESE)
Type
Traditional 510(k)

Official FDA 510(k) record

Device classification

Product code
GGT – Assay, Erythropoietin
Device class
Class II (moderate risk)
Regulation
21 CFR 864.7250
Specialty
Hematology

Other 510(k)s with product code GGT

510(k)DeviceApplicantDecision
K240182Access EPOGGT · Traditional Beckman Coulter, Inc.04/22/2024SE
K183088ADVIA Centaur Erythropoietin (EPO) assayGGT · Traditional Axis-Shield Diagnostics Limited08/02/2019SE
K052223Access Epo AssayGGT · Abbreviated Beckman Coulter, Inc.10/06/2006SE
K992799Sangui Biotech, Inc. Epo (Erythropoietin) Elisa KitGGT · Traditional Sangui Biotech, Inc.06/07/2000SE
K983203Immulite Epo, Model #'S Lkepz & LKEP1GGT · Traditional Diagnostic Products Corp.07/12/1999SE
K980737Advantage Chemiluminescence Erythropoietin ImmunoassayGGT · Traditional Nichols Institute Diagnostics03/23/1999SE
K952559Erythropoietin Immunoassay KitGGT · Traditional Nichols Institute05/29/1996SE
K954898Predicta Erythropoietin Kit (Modification)GGT · Traditional Genzyme Corp.02/05/1996SE
K936016Quantikine IVD Erythropoietin Enzyme Linked Immunosorbent Assay (Elisa)GGT · Traditional R&D Systems, Inc.07/19/1994SE
K931756Quantikine(Tm) Erythropoietin Human Serum ControlsGGT · Traditional R&D Systems, Inc.04/21/1994SE

More from R&D Systems, Inc.

510(k)DeviceDecision
K894943Clinigen Erythropoietin Human Serum Controls 1,2,3GGT · Traditional 10/10/1989SE

Questions and answers

When was Erythropoietin Enzyme Immunoassay cleared by the FDA?

Erythropoietin Enzyme Immunoassay (K882686) received a 510(k) decision of Substantially Equivalent on December 20, 1988, 173 days after the submission was received.

What is the product code of K882686?

The FDA product code is GGT – Assay, Erythropoietin, a Class II (moderate risk) device regulated under 21 CFR 864.7250.